Pernelle Noize
Overview
Explore the profile of Pernelle Noize including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Talbot D, Diop A, Mesidor M, Chiu Y, Sirois C, Spieker A, et al.
Stat Med
. 2025 Mar;
44(6):e70034.
PMID: 40079648
Targeted maximum likelihood estimation (TMLE) is an increasingly popular framework for the estimation of causal effects. It requires modeling both the exposure and outcome but is doubly robust in the...
2.
Maillard O, Bun R, Laanani M, Verga-Gerard A, Leroy T, Gault N, et al.
Therapie
. 2024 Jun;
79(6):659-669.
PMID: 38834394
Aim Of The Study: The French National Health Data System (SNDS) comprises healthcare data that cover 99% of the population (over 67 million individuals) in France. The aim of this...
3.
Gouverneur A, Favary C, Jove J, Rouyer M, Bignon E, Salvo F, et al.
Target Oncol
. 2023 Sep;
18(5):717-726.
PMID: 37682504
Background: Cardiovascular comorbidities are not contraindications of bevacizumab for metastatic colorectal cancer. Objective: We aimed to evaluate the impact of cardiovascular comorbidities before bevacizumab treatment on overall survival and cardiovascular...
4.
Begaud B, de Germay S, Noize P
Therapie
. 2023 Feb;
78(5):559-563.
PMID: 36841650
Although it can be difficult to define who should be considered an elderly person, the population aged 65 and over is experiencing the fastest demographic expansion and will represent almost...
5.
Zelmat Y, Conte C, Noize P, Vabre C, Pajiep M, Lafaurie M, et al.
Br J Clin Pharmacol
. 2022 Oct;
89(4):1338-1348.
PMID: 36285576
Aims: Pharmacovigilance signals of heart failure (HF) following exposure to protein kinase inhibitors (PKIs) have been detected in recent years. Our aim was to identify the PKIs most frequently associated...
6.
Mathieu C, Pambrun E, Benard-Laribiere A, Noize P, Faillie J, Bezin J, et al.
Eur J Epidemiol
. 2022 Sep;
37(10):1049-1059.
PMID: 36129659
Since pandemic start, patients may have faced difficulties in accessing to care and treatment. This study aimed at assessing the impact of COVID-19 pandemic and its control measures on the...
7.
Greillier L, Gauvrit M, Paillaud E, Girard N, Montegut C, Boulahssass R, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35159036
Systematic molecular profiling and targeted therapy (TKI) have changed the face of Non-Small Cell Lung Cancer (NSCLC) treatment. However, there are no specific recommendations to address the prescription of TKI...
8.
de Germay S, Berdai D, Noize P
Therapie
. 2022 Jan;
77(2):229-240.
PMID: 34973825
Since the early 2000s, the arrival of the so-called targeted therapies and immunotherapies have prolonged survival rates in many cancers. In parallel, post-marketing surveillance of anticancer drugs through pharmacoepidemiology has...
9.
Coppry M, Duret S, Berdai D, Miremont-Salame G, Fourrier-Reglat A, Haramburu F, et al.
Fundam Clin Pharmacol
. 2021 Oct;
36(2):421-426.
PMID: 34699080
Owing to a broad spectrum and low cost antimicrobial, cotrimoxazole is largely prescribed. However, its use is associated with various adverse drug reactions (ADRs) that warrant to ensure rational prescribing....
10.
Roux B, Bezin J, Morival C, Noize P, Laroche M
Expert Rev Pharmacoecon Outcomes Res
. 2021 Sep;
22(4):627-636.
PMID: 34525899
Background: Potentially inappropriate prescriptions (PIPs) in the older population remain a growing public health concern due to the many associated adverse events increasing healthcare service use and health costs. This...